TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Neupath Health Inc. ( (TSE:NPTH) ) has provided an announcement.
NeuPath Health Inc. reported a significant increase in its third-quarter financial results for 2025, with total revenue reaching $22.1 million, marking a 26% year-over-year growth. The company achieved positive cash flows and a 98% increase in Adjusted EBITDA, reflecting the success of its strategic initiatives to optimize clinic operations and enhance service delivery. This financial performance underscores NeuPath’s strong market positioning and potential for continued growth, benefiting stakeholders and reinforcing its leadership in chronic pain management.
The most recent analyst rating on (TSE:NPTH) stock is a Buy with a C$0.50 price target. To see the full list of analyst forecasts on Neupath Health Inc. stock, see the TSE:NPTH Stock Forecast page.
More about Neupath Health Inc.
NeuPath Health Inc. operates a network of clinics focused on delivering chronic pain treatment. The company is engaged in providing medical services through its clinics and offers additional services such as physician staffing for correctional institutions and contract research for pharmaceutical companies. NeuPath Health is committed to optimizing its medical facility operations and expanding its market presence.
Average Trading Volume: 84,241
Technical Sentiment Signal: Buy
Current Market Cap: C$19.83M
See more insights into NPTH stock on TipRanks’ Stock Analysis page.